Search

Omeros Corp

Gesloten

SectorGezondheidszorg

17.96 -0.44

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

17.21

Max

18.14

Belangrijke statistieken

By Trading Economics

Inkomsten

-38M

13M

Verkoop

19M

29M

K/W

Sectorgemiddelde

14.385

68.089

EPS

0.02

Winstmarge

46.381

Werknemers

175

EBITDA

-43M

14M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+58.96% upside

Dividenden

By Acuity

Volgende Winsten

16 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

287M

1.3B

Vorige openingsprijs

18.4

Vorige sluitingsprijs

17.96

Omeros Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 nov 2026, 21:07 UTC

Omeros Corporation shares are advancing, recovering from an early dip and reflecting a cumulative gain since Friday's close amid a recent downward trend.

6 nov 2026, 20:46 UTC

Omeros Corporation shares are lower, retracing from an early gain, amid broader market weakness and three consecutive sessions of losses.

5 nov 2026, 21:04 UTC

Omeros Corporation shares fell sharply, reaching their lowest point around midday and remaining well below the 20-day moving average.

2 nov 2026, 21:09 UTC

Omeros Corporation shares fell significantly, reaching their lowest point in early afternoon trading amid notable volatility and remaining within the one-month trading range.

30 okt 2026, 21:21 UTC

Shares down notably in after-market trading after volatile session.

29 okt 2026, 20:02 UTC

Omeros Corporation shares are advancing, reflecting strong trading activity with high volume, despite a slight pullback from earlier session highs.

28 okt 2026, 20:52 UTC

Omeros Corporation shares are trading lower in after-market hours, reflecting a significant decline in the broader market and falling to their lowest level of the day.

27 okt 2026, 22:56 UTC

Omeros Corporation's shares traded lower in after-market hours, remaining below their 20-day moving average despite a slight recovery from an earlier decline.

23 okt 2026, 19:36 UTC

Omeros Corp shares are declining, pulling back significantly from an earlier session high and remaining below Thursday's close.

22 okt 2026, 22:41 UTC

Omeros Corp is trading lower in after-market hours, continuing a downward trend and remaining significantly below Thursday's close and its 20-day moving average.

19 okt 2026, 20:07 UTC

Event

Omeros Corp shares advanced after the CHMP issued a negative opinion on its narsoplimab marketing authorization application for thrombotic microangiopathy.

16 okt 2026, 23:51 UTC

Event

Omeros Corp receives a negative opinion from the European Medicines Agency on its narsoplimab marketing authorization application for thrombotic microangiopathy.

15 okt 2026, 19:31 UTC

Omeros Corp shares are advancing amid a broader Pharmaceuticals sector rally, with unusually high trading volume reflecting increased investor activity.

13 okt 2026, 20:08 UTC

Omeros Corp shares are declining, reaching their lowest point just before the close amid a broader market trend of significant downward movement.

6 okt 2026, 20:07 UTC

Omeros Corp shares are declining, reaching their lowest point mid-morning and finishing well below the 20-day moving average amid weaker overall market performance.

5 okt 2026, 20:06 UTC

Omeros Corp is advancing, reflecting a gain from Friday's close, despite pulling back from an earlier session high.

2 okt 2026, 21:01 UTC

Omeros Corp is trading lower in after-market hours, continuing a downward trend that has lasted for six consecutive sessions.

1 okt 2026, 22:15 UTC

Omeros Corp is trading modestly higher in after-market hours following five consecutive sessions of declines, despite mixed signals in the broader market.

30 sep 2026, 19:46 UTC

Omeros Corp shares fell modestly Wednesday, continuing a decline observed over the past three trading days, despite remaining above the 20-day moving average.

28 sep 2026, 20:07 UTC

Omeros Corp shares are declining, following a broader market trend, after peaking early in the session and reaching a low before the close.

24 sep 2026, 19:35 UTC

Omeros Corp shares fell sharply after an earlier gain, despite remaining above the 20-day moving average and near the upper end of its one-month range.

23 sep 2026, 23:02 UTC

Omeros Corp's stock declined in after-market trading, dropping from Wednesday's close despite remaining above its 20-day moving average.

22 sep 2026, 20:02 UTC

News
Social Media

Omeros shares advance sharply after Cantor Fitzgerald upgraded the stock to Overweight, citing strong Yartemlea launch and reinstating a $22 price target.

21 sep 2026, 19:16 UTC

Omeros Corp has advanced during Monday's trading session, reaching a notable peak earlier in the day while remaining below its 20-day moving average.

18 sep 2026, 20:13 UTC

Omeros Corp's shares declined in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

17 sep 2026, 20:08 UTC

Omeros Corp is advancing sharply in Thursday's trading, having risen as much as 7% earlier before pulling back slightly, reflecting strong overall market gains.

16 sep 2026, 19:36 UTC

Omeros Corp is trading higher, having peaked earlier in the day, though it remains below its 20-day moving average amid a broader trend of lower closes.

15 sep 2026, 20:51 UTC

Omeros Corp shares are lower in after-market hours, continuing a five-session decline amid broader market pressures and elevated crude oil prices.

14 sep 2026, 23:06 UTC

Omeros Corp shares are lower in after-market hours, continuing a trend of declines amid broader market pressure from rising crude oil prices.

10 sep 2026, 20:03 UTC

Omeros Corp shares are lower today, continuing a decline since Wednesday. Trading volume is notably high, reflecting increased investor activity.

Peer Vergelijking

Prijswijziging

Omeros Corp Prognose

Koersdoel

By TipRanks

58.96% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 27.5 USD  58.96%

Hoogste 33 USD

Laagste 22 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Omeros Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat